Associate Professor, Medicine, Indiana University School of Medicine
Internal Medicine
Dr. Larry D. Cripe, MD
|
|
Give Review
Larry Cripe is an expert in the field of Internal Medicine. He went to medical school at Rush Medical College. He has 2 awards "Indianapolis Monthly" and "Top MD". Larry Cripe is a published doctor and has 52 publications published. The lastest was: 'Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma.' Larry Cripe is registered with Medicare and accepts Medicare payments.
Publications
- Cyclophosphamide/fludarabine nonmyeloablative allotransplant for Acute myeloid leukemia.
- Pilot study of erlotinib in patients with Acute myeloid leukemia.
- REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated Acute myeloid leukaemia.
- A phase 1b/2 study of combination vosaroxin and cytarabine in patients with relapsed or refractory Acute myeloid leukemia.
- Randomized, dose-escalation study of the p38? MAPK inhibitor SCIO-469 in patients With myelodysplastic syndrome.
- Functional Pathway Analysis Using SCNP of FLT3 Receptor Pathway Deregulation in AML Provides Prognostic Information Independent from Mutational Status.
- A Noncanonical Flt3ITD/NF-?B Signaling Pathway Represses DAPK1 in Acute Myeloid Leukemia.
- Illness appraisal, religious coping, and psychological responses in men with advanced Cancer.
- Trustworthiness.
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients With FLT3 mutant AML in first relapse.
- Thrice weekly azacitidine does not improve Hematological responses in lower-risk myelodysplastic syndromes: A study of the Hoosier Oncology Group.
- Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.
- Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed Acute myeloid leukemia: a randomized, placebo-cont...
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic Leukemia.
- Dying pretty.
- A piece of my mind. Giving up.
- Foreword. The discovered story: the evolution of truth in Cancer narratives.
- Treating low-risk Myelodysplastic syndromes in the community setting.
- Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients With relapsed or refractory multiple myelo...
- A piece of my mind. Hope is the thing With feathers.
- Desensitization to imatinib in patients with Leukemia.
- Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic Leukemia.
- A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin Lymphomas: a Hoosier Oncology Group Study.
- Oncologist Assisted Spiritual Intervention Study (OASIS): patient acceptability and initial evidence of effects.
- Teaching patients how to improve communication With their health care providers: a unique workshop experience.
- Thrombopoietin administered during induction chemotherapy to patients with Acute myeloid leukemia induces transient morphologic changes that may resemble chronic myelo...
- Music imagery for adults with Acute leukemia in protective environments: a feasibility study.
- Failure of three novel regimens to improve outcome for patients with relapsed or refractory Acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group.
- Constitutive c-jun N-terminal kinase activity in Acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
- 12-O-Tetradecanoylphorbol-13-acetate in Acute myeloid leukemia.
- Phase II trial of subcutaneous recombinant human interleukin 11 With subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients With a...
- Phase II study of low-dose topotecan in Myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study.
- Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory Acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995.
- Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds With activity of JNK, the c-jun N-terminal kinase.
- Role for c-jun N-terminal kinase in treatment-refractory Acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferation.
- Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for Acute myeloid leukemia/m...
- Low expression of the Myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials.
- Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's Lymphoma.
- A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk Myelodysplastic syndrome.
- Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients With multiple myeloma.
- A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory Acute leukemia.
- Acute myeloid leukemia in adults.
- Adult Acute leukemia.
- Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's Lymphoma.
- The exodus subfamily of CC chemokines inhibits the proliferation of chronic myelogenous Leukemia progenitors.
- A woman With facial papules and pulmonary nodules.
- Practical recommendations on the use of lenalidomide in the management of Myelodysplastic syndromes.
- Malignant Disorders of megakaryocytes.
- Complex regulation of macrophage colony-stimulating factor in the HL-60 promyelocytic Cell line.
- Hyperleukocytic Leukemias and leukostasis: a review of pathophysiology, clinical presentation and management.
- Association of the protein kinases c-Bcr and Bcr-Abl With proteins of the 14-3-3 family.
Schools
Rush Medical College Of Rush University
Duke University Med Center
Rush Presby St Luke39s M C
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Bladder Cancer
- Breast Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
- Internal Medicine
Accepted Insurances
Awards
- Indianapolis Monthly
- Top MD
Education
-
Duke University Hospital -
Rush University Medical Center -
Rush Medical College
Drug Facts
| NPI NUMBER | 1225094741 | |
| NPPES Provider LastName | CRIPE | |
| NPPES Provider FirstName | LARRY | |
| NPPES Provider ZIPCode | 462025112 | |
| NPPES Provider State | IN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 405.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 11.0 | |
| Percent Opioid Claims | 2.72 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1225094741 |
| Last Name Of The Provider | CRIPE |
| First Name Of The Provider | LARRY |
| View All |
Similar Doctors
|
Dr. Stephen E. Rubenstein, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Louis M. Wright, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Garson D. Roodman, MD |
|
Dr. Niraj Gupta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Muhammad Arif, MD |
|
|
Dr. Shadia I. Jalal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jordan M. Schmitt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shivaji R. Gunale, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wanita C. Kumar, MD
This Doctor is OpenDoctor Recommended.
|